Halozyme Therapeutics (HALO) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Halozyme Therapeutics (HALO) over the past year, gaining 298.5% versus a gain of 69.6%. Over five years, RVMD leads with a +604.1% price change compared with +192.4% for HALO. Revolution Medicines is the larger company by market cap ($40.67 billion vs $12.53 billion), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | RVMD |
|---|---|---|
| Share price | $110.42 | $189.76 |
| Market cap | $12.53B | $40.67B |
| 1-day change | +0.53% | +0.87% |
| YTD return | +64.07% | +138.24% |
| 1-year return | +69.59% | +298.53% |
| 5-year return | +192.43% | +604.12% |
| P/E ratio (TTM) | 32.29 | — |
| Forward P/E | 10.39 | — |
| EPS (TTM) | $3.42 | $-8.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $0 |
| Revenue growth (YoY) | +37.55% | — |
| Net income (latest FY) | $316.89M | $-1.13B |
| Gross margin | 83.62% | — |
| Operating margin | 33.58% | — |
| Net margin | 22.69% | — |
| 52-week high | $116.85 | $224.31 |
| 52-week low | $61.23 | $47.45 |
| Distance from 52-week high | -5.50% | -15.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.84% | +36.40% |
| Average volume | 2.19M | 1.95M |
| Shares outstanding | 113.50M | 214.34M |
| Employees | 423 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revolution Medicines is about 3.2 times larger than Halozyme Therapeutics by market value ($40.67B vs $12.53B).
- RVMD has outperformed HALO by 228.9 percentage points over the past year.
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
HALO vs RVMD FAQ
Which is bigger, Halozyme Therapeutics or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.67B compared with $12.53B for Halozyme Therapeutics (HALO).
Which stock has performed better over the past year, HALO or RVMD?
RVMD returned +298.53% over the past 12 months, compared with +69.59% for HALO (price return, excluding dividends). Past performance does not predict future results.
Are Halozyme Therapeutics and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.